Incidence of Gastrointestinal Perforation in Users of ACTEMRA® (Tocilizumab), Rituxan® (Rituximab), Abatacept and Anti-Tumor Necrosis Factor Alpha Agents First published 23/12/2016 Last updated 14/03/2024 EU PAS number:EUPAS16960 Study Finalised